Company

Overview

Everist Genomics is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies which help physicians improve medical outcomes and reduce the total cost of care. EGI's innovative products successfully integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology which until now has been confined to the hospital setting.

EGI is a closely held, privately owned company, headquartered in Ann Arbor, Michigan. The principle shareholders of EGI are large family investment offices headquartered in Denver, Colorado; Sioux Falls, South Dakota; New York City and Naples, Florida.

EGI was formed two years ago by combining the assets, product portfolios, capabilities and IP of Genetics Squared, Inc., Angiologix Inc. and MedicalAlgorithmics, S.A. Everist Genomics has successfully completed several cash-based company and product acquisitions, all financed by the current family office shareholder base.  EGI’s patent protected products aid physicians in:

1. Early diagnosis of diseases (such as cancer, cardiovascular disease and metabolic disease), long before there are any detectable symptoms and thereby enabling early and more effective treatment while also reducing healthcare costs and saving lives.
   
   Example of EGI products:
   
   AngioDefender: a non-invasive sensor technology device for the early diagnosis of atherosclerosis and cardiovascular disease years before a patient has detectable symptoms.
   
   CardioDefender, the world’s first smartphone based, real-time, beat-by-beat, quantitative heart arrhythmia monitor which enables physicians to monitor a patient’s heart rhythm and receive automated alerts from anywhere in the world.  The technology provides the quality of heart rhythm monitoring which has in the past been confined to the hospital setting utilizing proprietary software, algorithms, smartphone and Bluetooth technology.
2. Disease prognosis products identify individual patients at high-risk of experiencing a recurrence of a cancer for which they have been previously treated.  This enables physicians to administer adjuvant (chemo-radiation) therapy which improves disease free rates and reduces patient mortality.  This technology also saves the healthcare system money; adjuvant therapy costs just 20% of post cancer-recurrence treatment.
   
   Example of EGI product:  OncoDefender - CRC, a molecular diagnostic which predicts the risk of recurrence in patients previously treated for colorectal cancer by measuring gene expression levels that are highly accurate predictors of cancer recurrence.
3. Therapeutic selection tests which help physicians identify which therapeutics a patient’s disease is most likely to respond well to.  This is particularly important in cancer and infectious diseases where the specific type of tumor or infection a patient has will determine which drug will be the optimal treatment in terms of efficacy and safety.
   
   Example of EGI product – OncoSelector, a molecular diagnostic test which helps physicians select the specific chemotherapy which a colon cancer patient is likely to best respond to and tolerate the side-effects associated with a particular chemotherapy.

International Joint-Venture Companies:
EGI commercializes their products globally; in India, China and Japan, EGI is establishing joint-venture companies with leading multi-national corporate partners to implement local manufacturing, marketing and sales.  In 2011 EGI established the first of these joint-venture companies in India with the Manipal Group, a leading multi-national healthcare company.